INTI
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies for prostate and lung cancer utilizing SUBA-Itraconazole, an oral formulation of the drug itraconazole; and conducted a positive Phase 2b study of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.00 | $0 | -$1M |
| 2025 Q4 | -0.01 | $0 | -$601,165 |
| 2025 Q3 | -0.00 | $0 | -$761,245 |
| 2025 Q2 | -0.00 | $0 | -$583,991 |
| 2025 Q1 | -0.00 | $0 | -$1M |
| 2024 Q4 | -0.01 | $0 | -$771,441 |
| 2024 Q3 | -0.00 | $0 | -$720,438 |
| 2024 Q2 | -0.00 | $0 | -$583,079 |